A Pilot Study of Vigil Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary) ; Pembrolizumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Gradalis
- 31 Aug 2018 Biomarkers information updated
- 26 Sep 2017 Status changed from active, no longer recruiting to completed.
- 27 Jul 2017 Status changed from recruiting to active, no longer recruiting.